Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

12.47 +0.54 (+4.54%)
Streaming Delayed Price Updated: 3:14 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
From Xencor, Inc.
Via Business Wire
News headline image
Top 5 Health Care Stocks That May Collapse In February ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Xencor to Present at the SVB Securities Global Biopharma Conference
From Xencor, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗
 
Via Benzinga
News headline image
Why Shares of Zencor Rose This Week ↗
The clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago. 
Via The Motley Fool
Xencor's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Xencor's Return On Capital Employed Overview ↗
  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗
 
Via Benzinga
News headline image
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
News headline image
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗
 
Via Benzinga
News headline image
Xencor Reports Third Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
From Xencor, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 7, 2022 ↗
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
News headline image
Xencor Earnings Preview ↗
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Xencor will report an... 
Via Benzinga
News headline image
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 ↗
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
News headline image
Xencor Appoints Nancy Valente, M.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Second Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
From Xencor, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
During Monday's trading, 1214 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.